Medtronic Seeking Long-Distance Runners Who Benefit From Medical Technology
Medtronic, Inc. (NYSE: MDT) announced today applications are open to runners around the world who benefit from medical technology to represent their country on the 2014 Medtronic Global Heroes team. The 2014 Medtronic Twin Cities Marathon weekend will take place October 3-5, 2014. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - March 16, 2014 Category: Cardiology Source Type: news
Volcano Corporation Presentation At Barclays Conference To Be Webcast
Volcano Corporation (Nasdaq: VOLC) said today that it will be participating in the Barclays Global Healthcare Conference 2014 on Tuesday, March 11. The presentation by John Dahldorf, chief financial officer, will begin at 11:15 a.m., Eastern Daylight Time (8:15 a.m., Pacific Daylight Time). (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - March 10, 2014 Category: Cardiology Source Type: news
Valve Wars, Part II: Edwards vs. Medtronic
Last summer the District Court of Mannheim issued an injunction prohibiting Medtronic from selling its CoreValve and CoreValve Evolut transcatheter valves in Germany. The injunction was based on the Spenser patent. Today Medtronic announced that the European Patent Office has revoked the Spenser patent in its entirety. This outcome is a big win for Medtronic in Europe, although the ruling is subject to appeal by Edwards. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - March 7, 2014 Category: Cardiology Source Type: news
Can Near-Infrared Imaging Predict Heart Attack Risk?
What causes a heart attack? Is it a physical narrowing in the coronary artery, a blockage that can be seen on angiography? Or is it more likely the eruption of a lipid-rich plaque, a so-called vulnerable plaque, that may not look significant in percent stenosis during a standard catheterization? Today MedStar Heart Institute and Infraredx announced enrollment of the first patient in the Lipid-Rich Plaque (LRP) Study, which will involve 100 centers worldwide and has a target enrollment of 9,000 patients. As Infraredx founder Dr. James Muller states, "Once completed, the LRP Study could redefine the role of intravascular ima...
Source: News from Angioplasty.Org - February 27, 2014 Category: Cardiology Source Type: news
The Incredible Shrinking Cardiac Devices
The "world's smallest, minimally invasive cardiac pacemaker," Medtronic's Micra™ Transcatheter Pacing System, was implanted last week for the first time in the United States. This implantation comes just two-plus months after its first in-human implantation, performed in Austria. Both implantations are part of a single-arm multi-center clinical trial which will enroll up to 780 patients. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 25, 2014 Category: Cardiology Source Type: news
RENLANE™ Renal Denervation System from Cordis Gets CE Mark
Even while panels and journals continue to debate the efficacy of renal denervation in treating resistent hypertension, a situation brought to the forefront by Medtronic's announcement in January that its pivotal U.S. renal denervation trial failed to meet its pre-specified endpoint, the Conformité Européenne has bestowed its CE Mark on a brand new system from Cordis Corporation. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 25, 2014 Category: Cardiology Source Type: news
Volcano Reports Fourth Quarter Revenues Increase Six Percent On A Constant Currency Basis
Volcano Corporation (Nasdaq: VOLC) today reported results for the fourth quarter and all of 2013. For the quarter ended December 31, 2013, Volcano reported revenues of $103.3 million versus revenues of $102.5 million in the same period a year ago. On a constant currency basis, revenues increased six percent year-over-year after adjusting for a negative impact of approximately $5.5 million from foreign currency. The company reported a net loss on a GAAP basis of $20.5 million, or $0.38 per share, in the fourth quarter of 2013, versus net income of $2.5 million, or $0.04 per diluted share, in the same period a year ago. (Sou...
Source: News from Angioplasty.Org - February 24, 2014 Category: Cardiology Source Type: news
Medtronic Announces Global Launch of Miniature Cardiac Monitor, Reveal LINQ™ ICM
Medtronic, Inc. (NYSE: MDT) today announced U.S. Food and Drug Administration (FDA) 510(k) clearance, CE (Conformité Européenne) Mark, and the global launch of its Reveal LINQ Insertable Cardiac Monitor (ICM) System, the smallest implantable cardiac monitoring device available for patients. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 21, 2014 Category: Cardiology Source Type: news
Medtronic Reports Third Quarter Earnings
Medtronic, Inc. (NYSE: MDT) today announced financial results for its third quarter of fiscal year 2014, which ended January 24, 2014. The company reported worldwide third quarter revenue of $4.163 billion, compared to the $4.027 billion reported in the third quarter of fiscal year 2013, an increase of 4 percent on a constant currency basis after adjusting for a $41 million negative foreign currency impact or 3 percent as reported. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 21, 2014 Category: Cardiology Source Type: news
Medtronic Launches New Peripheral Angioplasty Catheter in Europe
Today Medtronic, Inc. (NYSE: MDT) announced the European launch of its latest product to address the problems of peripheral artery disease (PAD), the "TOTAL Across" crossing catheter, intended for use in the lower extremities, specifically those arterial blockages below the knee that often are the cause of critical limb ischemia. Today's announcement by Medtronic adds to their portfolio of peripheral devices, including the IN.PACT drug-eluting balloon, and several balloon catheters designed for use in challenging narrow below-the-knee blockages. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 13, 2014 Category: Cardiology Source Type: news
DUTCH PEERS: Third Generation Drug-Eluting Stents from Medtronic and Boston Scientific Are (Almost) Equivalent
Are third generation drug-eluting stents interchangeable? And what exactly is a "third generation" drug-eluting stent anyway? These were questions addressed by the DUTCH PEERS randomized clinical trial, recently published in The Lancet. The results showed that the Resolute Integrity was non-inferior to the Promus Element. There was, however, one parameter in which the two stents were not the same: longitudinal stent deformation. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 12, 2014 Category: Cardiology Source Type: news
Medtronic to Announce Financial Results for Its Third Quarter of Fiscal Year 2014
Medtronic, Inc. (NYSE: MDT) announced today it will report financial results for the third quarter of its fiscal year 2014 on Tuesday, February 18, 2014. Medtronic will host a webcast at 7:00 a.m. CST to discuss financial results for its third quarter. The webcast can be accessed by clicking on the Investors link through the Medtronic website at www.medtronic.com on February 18, 2014. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 11, 2014 Category: Cardiology Source Type: news
Capsule-Sized Leadless Pacemakers May Lead the Way in Heart Rhythm Management
Is the future of implantable pacemakers a miniaturized leadless capsule, no bigger than a coin, delivered non-surgically via a catheter, much like a stent during angioplasty? Looking at the recent news from two of the leading manufacturers of pacemakers, one would conclude in the affirmative. Last week, St. Jude Medical announced the first U.S. implantation of their leadless Nanostim pacemaker (press release below) at Mt. Sinai Hospital in New York. The next-in-line challenger to St. Jude is Medtronic, who announced the first human implant of its leadless Micra catheter in December. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 10, 2014 Category: Cardiology Source Type: news
CVS To Stop Selling Cigarettes and Tobacco at a Cost of $2 Billion Annually
CVS/pharmacy made an extraordinary announcement today: the company has decided to stop selling cigarettes and all tobacco products by October 1 of this year. As stated by Larry Merlo, President and CEO of CVS, "Tobacco products have no place in a setting where health care is delivered." (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 6, 2014 Category: Cardiology Source Type: news
Volcano Corporation Schedules Fourth Quarter Conference Call, Webcast
Volcano Corporation (NASDAQ: VOLC) today announced that it will report its operating results for the fourth quarter of fiscal 2013 on Monday, February 24. The company will hold a conference call to discuss its financial results and operating activities open to all interested parties at 2 p.m., Pacific Standard Time (5 p.m., Eastern Standard Time), Monday, February 24, hosted by Scott Huennekens, president and chief executive officer, and John Dahldorf, chief financial officer. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 4, 2014 Category: Cardiology Source Type: news
